These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 17096291

  • 1. Metabolic diseases.
    Balfe A, Perry L.
    IDrugs; 2006 Nov; 9(11):754-5. PubMed ID: 17096291
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ, Nunez DJ.
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [Abstract] [Full Text] [Related]

  • 4. Experimental drugs take aim at obesity.
    Vastag B.
    JAMA; 2003 Apr 09; 289(14):1763-4. PubMed ID: 12684341
    [No Abstract] [Full Text] [Related]

  • 5. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
    Naruszewicz M.
    Przegl Lek; 2006 Apr 09; 63 Suppl 4():7-8. PubMed ID: 16967707
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. All in one: Researchers create combination drugs for diabetes and obesity.
    Chakradhar S.
    Nat Med; 2016 Jul 07; 22(7):694-6. PubMed ID: 27387879
    [No Abstract] [Full Text] [Related]

  • 11. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
    Harley EA, Levens N.
    Curr Opin Investig Drugs; 2003 Oct 07; 4(10):1179-89. PubMed ID: 14649209
    [Abstract] [Full Text] [Related]

  • 12. Exenatide. Amylin/Eli Lilly.
    Giannoukakis N.
    Curr Opin Investig Drugs; 2003 Apr 07; 4(4):459-65. PubMed ID: 12808888
    [Abstract] [Full Text] [Related]

  • 13. Recent advances in peptide-based therapy for Type 2 diabetes and obesity.
    Conlon JM, Flatt PR, Bailey CJ.
    Peptides; 2021 Nov 07; 145():170652. PubMed ID: 34555424
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hypoglycemic agents in the management of type 2 diabetes mellitus.
    Ho J, Leung AK, Rabi D.
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan 07; 5(1):66-73. PubMed ID: 22074580
    [Abstract] [Full Text] [Related]

  • 17. Emergence of promising therapies in diabetes mellitus.
    Akkati S, Sam KG, Tungha G.
    J Clin Pharmacol; 2011 Jun 07; 51(6):796-804. PubMed ID: 20705952
    [Abstract] [Full Text] [Related]

  • 18. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
    Flatt PR.
    Diab Vasc Dis Res; 2007 Jun 07; 4(2):151-3. PubMed ID: 17654450
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.